Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Increased CD271 expression by the NF-kB pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib
Authors
Keywords
-
Journal
Cell Discovery
Volume 1, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-10-27
DOI
10.1038/celldisc.2015.30
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mitochondrial oxidative stress is the achille’s heel of melanoma cells resistant to Braf-mutant inhibitor
- (2015) Paola Corazao-Rozas et al. Oncotarget
- CD271 is an imperfect marker for melanoma initiating cells
- (2015) Yann Cheli et al. Oncotarget
- PDGFRα up-regulation mediated by Sonic Hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation
- (2015) Francesco Sabbatino et al. Oncotarget
- A stress-induced early innate response causes multidrug tolerance in melanoma
- (2014) D Ravindran Menon et al. ONCOGENE
- The Nerve Growth Factor Receptor CD271 Is Crucial to Maintain Tumorigenicity and Stem-Like Properties of Melanoma Cells
- (2014) Torben Redmer et al. PLoS One
- The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF
- (2014) M. P. Smith et al. Cancer Discovery
- A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
- (2014) D. J. Konieczkowski et al. Cancer Discovery
- The IκB kinase complex in NF-κB regulation and beyond
- (2013) Michael Hinz et al. EMBO REPORTS
- Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner
- (2013) M. Cerezo et al. MOLECULAR CANCER THERAPEUTICS
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
- (2012) Jennifer Landsberg et al. NATURE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human CD271-Positive Melanoma Stem Cells Associated with Metastasis Establish Tumor Heterogeneity and Long-term Growth
- (2011) G. Civenni et al. CANCER RESEARCH
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metformin inhibits melanoma development through autophagy and apoptosis mechanisms
- (2011) T Tomic et al. Cell Death & Disease
- Cell-Selective Inhibition of NF- B Signaling Improves Therapeutic Index in a Melanoma Chemotherapy Model
- (2011) T. Enzler et al. Cancer Discovery
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth
- (2010) T Botton et al. CELL DEATH AND DIFFERENTIATION
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271
- (2010) Alexander D. Boiko et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- The MAPK pathway in melanoma
- (2009) Leslie A Fecher et al. CURRENT OPINION IN ONCOLOGY
- In Vitro and In Vivo Anti-Melanoma Effects of Ciglitazone
- (2009) Thomas Botton et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Identification of cells initiating human melanomas
- (2008) Tobias Schatton et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started